Mon panier

Human TNFSF11 / RANKL / CD254 Protein, Fc Tag

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
RAL-H5265-50ug
$360.00
RAL-H5265-1mg (500ug X 2)
$3035.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    RANKL, CD254, TRANCE, OPGL, ODF

  • Source

    Human TNFSF11, Fc Tag (RAL-H5265) is expressed from human 293 cells (HEK293). It contains AA Gly 64 - Asp 245 (Accession # AAC51762.1).

    Predicted N-terminus: Pro

    Request for sequence
  • Molecular Characterization

    TNFSF11 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a human IgG1 Fc tag at the N-terminus.

    The protein has a calculated MW of 46.9 kDa. The protein migrates as 50-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    TNFSF11 SDS-PAGE

    Human TNFSF11, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

  • Bioactivity-ELISA

     TNFSF11 ELISA

    Immobilized Human RANK, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. RAK-H5251) at 0.5 μg/mL (100 μL/well) can bind Human TNFSF11, Fc Tag (Cat. No. RAL-H5265) with a linear range of 0.1-3 ng/mL (QC tested).

    Protocol
  •  TNFSF11 ELISA

    Immobilized Human OPG, His Tag (Cat. No. TNB-H5220) at 10 μg/mL (100 μL/well) can bind Human TNFSF11, Fc Tag (Cat. No. RAL-H5265) with a linear range of 0.3-2 ng/mL (Routinely tested).

    Protocol
  • Bioactivity-SPR

     TNFSF11 SPR

    Captured Human RANK, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. RAK-H5251) on CM5 chip via Anti-Mouse antibodies surface can bind Human TNFSF11, Fc Tag (Cat. No. RAL-H5265) with an affinity constant of 0.574 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

    Protocol
  • Bioactivity-BLI

     TNFSF11 BLI

    Loaded Human RANK, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. RAK-H5251) on AMC Biosensor, can bind Human TNFSF11, Fc Tag (Cat. No. RAL-H5265) with an affinity constant of 0.205 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Receptor activator of nuclear factor kappa-B ligand (RANKL), also known as tumor necrosis factor ligand superfamily member 11 (TNFSF11), TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF), is known as a type II membrane protein and is a member of the tumor necrosis factor (TNF) superfamily. RANKL, through its ability to stimulate osteoclast formation and activity, is a critical mediator of bone resorption and overall bone density. Some findings also suggestion some cancer cells, particularly prostate cancer cells, can activate an increase in bone remodeling and ultimately increase overall bone production.[17] This increase in bone remodeling and bone production increases the overall growth of bone metastasizes. The overall control of bone remodeling is regulated by the binding of RANKL with its receptor or its decoy receptor, respectively, RANK and OPG.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Tumor necrosis factor ligand superfamily member 11

  • Catégorie:

  • Nombre de médicaments répertoriés:

    18 Détails

  • Nombre de médicaments cliniques:

    18 Détails

  • Étape de développement la plus élevée:

    Approved

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte